

# Carbon Reduction Plan

Supplier name: ...GSK.....

Publication date: .....16<sup>th</sup> February 2026.....

**\*Note:** Due to the timing of availability of new emissions data, GSK is republishing data from the 2025 Carbon Reduction Plan as an interim measure. GSK expects to publish a 2026 Carbon Reduction Plan with new data in April 2026.

## Commitment to achieving Net Zero

**GSK** is committed to achieving Net Zero emissions by **2045**.

## Baseline Emissions Footprint

Baseline emissions are a record of the greenhouse gases that have been produced in the past and were produced prior to the introduction of any strategies to reduce emissions. Baseline emissions are the reference point against which emissions reduction can be measured.

<b>Baseline Year: 2020</b>	
<b>Additional Details relating to the Baseline Emissions calculations.</b>	
Historic baseline year emissions from 2020 onwards were restated in 2023 following the demerger of GSK's Consumer Healthcare business to form Haleon in July 2022. The restatement excludes historic emissions that were allocated to the consumer healthcare business unit.	
<b>Baseline year emissions:</b>	
<b>EMISSIONS</b>	<b>TOTAL (tCO<sub>2</sub>e)</b>
<b>Scope 1</b>	710,529
<b>Scope 2</b>	168,854

<b>Scope 3</b> (Included Sources)	9,949,039
<b>Total Emissions</b>	10,828,422

## Current Emissions Reporting

<b>Reporting Year: 2025</b>	
<b>EMISSIONS</b>	<b>TOTAL (tCO<sub>2</sub>e)</b>
<b>Scope 1</b>	520,418 (based on 2024 data)
<b>Scope 2</b>	43,541 (based on 2024 data)
<b>Scope 3</b> (Included Sources)	8,983,956 (the latest data available for scope 3 is based on 2023 activity)
<b>Total Emissions</b>	9,628,595

## Emissions reduction targets

In 2023, The Science Based Targets initiative (SBTi) approved GSK's net zero target for 2045 in line with its Corporate Net-Zero Standard, the world's only framework for corporate net zero target setting in line with climate science. This commitment applies for both GSK and ViiV operations.

### *Near term target*

GSK and ViiV commits to disclose and reduce absolute scope 1 & 2 (market approach) by 80% and scope 3 GHG emissions from Purchased goods and services, Fuel & Energy Related Activities, Upstream transportation and distribution, Waste Generated in Operations, Business travel, Employee commuting, Use of sold products and End-of-life treatment of sold products by 80% by 2030 from a 2020 base year. GSK discloses against Downstream Transportation and distribution but those categories are currently excluded from the target due to data improvement needs. GSK does, however, continue to maximise the transition from air to sea freight across its portfolio, and to collaborate with its peers to improve container load and procurement of sustainable fuels for the sector.

In line with GSK's reporting cycle, operational data (Scope 1 and 2) is readily available for 2024. For Scope 3, further reconciliation of emissions associated with cost of goods is required, therefore reported using figures from the previous fiscal year (which are externally


audited annually). We are working with strategic data partners to improve agility in Scope 3 reporting in the future.

### Long term target

GSK and ViiV commit to reduce absolute scope 1 & 2 (market approach) by 90% and scope 3 GHG emissions from Purchased goods and services, Capital goods, Fuel & Energy Related Activities, Upstream transportation and distribution, Waste Generated in Operations, Business travel, Employee commuting, Use of sold products and End-of-life treatment of sold products and investments by 90% by 2045 from a 2020 base year.

## Our value chain carbon footprint

We have mapped our carbon footprint across our value chain to ensure we have a clear understanding of where to focus our efforts, which informs our pathway to net zero.




February 2025

(Infographic numbers show GSK and ViiV footprint across scopes 1,2 and 3 using 2023 numbers).

## Our pathway to net zero

The graph below shows our projected carbon reduction pathway to 2030 and 2045 across the different parts of our carbon footprint, along with our planned carbon credits.



February 2025


# Carbon Reduction Projects (applicable for both GSK and ViiV)

## Completed Carbon Reduction Initiatives

In 2024, we reduced our Scope 1 & 2 carbon emissions by 12% compared with 2023, and by 36% compared with our 2020 baseline. The reduction in our Scope 1 & 2 carbon emissions in 2024 was primarily driven by energy efficiency measures in our manufacturing processes, our ongoing transition to renewable energy and reducing propellant emissions during the manufacturing of inhalers. In 2024, we reached 90% imported renewable electricity, 7 percentage points higher than the 83% we used in 2023. We also have a longer-term target to have 100% of all electricity imported and from self-generated from renewable sources by 2030, and in 2024 we achieved 90%.

GSK's carbon reduction initiatives addressing emissions across scopes 1, 2 and 3 are shown in the graphic below:

## Priority actions to reduce emissions



## Declaration and Sign Off

This Carbon Reduction Plan has been completed in accordance with PPN 06/21 and associated guidance and reporting standard for Carbon Reduction Plans.

Emissions have been reported and recorded in accordance with the published reporting standard for Carbon Reduction Plans and the GHG Reporting Protocol corporate standard<sup>1</sup> and uses the appropriate Government emission conversion factors for greenhouse gas company reporting<sup>2</sup>.

Scope 1 and Scope 2 emissions have been reported in accordance with SECR requirements, and the required subset of Scope 3 emissions have been reported in

<sup>1</sup><https://ghgprotocol.org/corporate-standard>

<sup>2</sup><https://www.gov.uk/government/collections/government-conversion-factors-for-company-reporting>

accordance with the published reporting standard for Carbon Reduction Plans and the Corporate Value Chain (Scope 3) Standard<sup>3</sup>.

This Carbon Reduction Plan has been reviewed and signed off by the board of directors (or equivalent management body).

**Signed on behalf of the Supplier:**

A rectangular box containing a handwritten signature in black ink. The signature appears to be 'clund' in a cursive style.

Claire Lund, VP Sustainability, GSK

Date: 16<sup>th</sup> February 2026

---

<sup>3</sup><https://ghgprotocol.org/standards/scope-3-standard>